[Locally advanced pancreatic cancer that enlarged after administration of gemcitabine and responded to oral TS-1--a case report].
We administered oral TS-1 alone for locally advanced pancreatic cancer that did not respond to gemcitabine (GEM). A 56-year-old man was admitted to our hospital because of obstructive jaundice due to stage III pancreatic head cancer. We performed chemotherapy using GEM at a dose of 1,000 mg/m(2) after reduction of jaundice by PTCD and stenting. Once the tumor was reduced, enlargement was confirmed after 8 months, and cholangitis appeared due to stent obstruction. After PTCD and stenting (stent in stent) were performed again,we administered oral TS-1 alone at a dose of 100 mg/body. We achieved antitumor activity again using TS-1. It is suggested that TS-1 is a useful second-line agent for pancreatic cancer.
Tanaka
Shouichi
S
Dept. of Gastroenterology, National Hospital Organization Iwakuni Clinical Center.
Fujii
Masakuni
M
Goubaru
Motohiro
M
Ohta
Takeyuki
T
Ogata
Masatoshi
M
Makino
Yasuhiro
Y
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D041781:Jaundice, Obstructive / Q000209:etiology / Q000628:therapy; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage*; D010190:Pancreatic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D011725:Pyridines / Q000008:administration & dosage*; D015607:Stents; D005641:Tegafur / Q000008:administration & dosage*; D000093542:Gemcitabine
D004338:Drug Combinations; D011725:Pyridines; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000093542:Gemcitabine